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LETTERS
Mycobacterium 
bohemicum and 
Cervical 
Lymphadenitis 
in Children
To the Editor: Members of the 
genus  Mycobacterium are well-es-
tablished causes of granulomatous 
lymphadenitis in children. M. bohe-
micum was ﬁ  rst described in 1998 in a 
patient with Down syndrome (1). The 
organism is characterized by a unique 
16S rRNA gene sequence (1) and has 
been isolated from humans, animals, 
and the environment (2). Published 
data on M. bohemicum are limited to 
the original species description and 5 
additional case reports (3–6).
We report on 4 cases of cervical 
lymphadenitis caused by M. bohemic-
um that occurred in 4 children (2 boys, 
2 girls) from Austria during 2002–
2006. Age range of the children was 
2.5–3.5 years (Table). Each child was 
admitted to the hospital with a history 
of 2–3 weeks of submandibular swell-
ing that did not respond to oral antimi-
crobial therapy.
Physical examination showed 
enlarged cervical lymph nodes under 
normal skin. Laboratory evaluation 
showed leukocyte and differential 
counts within normal limits and a neg-
ative result (<2 mg/L) for C-reactive 
protein. Ultrasonography demonstrat-
ed enlarged lymph nodes with hetero-
geneous echo and a central lacuna-like 
lesion.
Lymph nodes were excised from 
each patient. Histologic examination 
of the nodes demonstrated granuloma-
tous and partly necrotizing inﬂ  amma-
tion (Table). PCR results for M. tuber-
culosis complex were negative. For 
3 patients, the affected lymph nodes 
were completely removed and no an-
timicrobial therapy was prescribed. 
For the other patient, removal of the 
affected lymph node was incomplete, 
and clarithromycin and rifampicin for 
3 months were prescribed. All patients 
remained healthy for >12 months after 
therapy.
From all patients, parts of the 
excised lymph nodes were directly 
used for acid-fast smear and culture 
for mycobacteria. All specimens were 
processed according to national guide-
lines (the German Institute for Stan-
dardization [DIN], Diagnostics for 
Tuberculosis DIN 58943-3, Cultural 
Methods for Isolation of Mycobacte-
ria, Berlin: Beuth; 1996.)
Slides for microscopic exami-
nation were prepared directly from 
minced lymph nodes before decontam-
ination, and the tissue was stained ac-
cording to the Ziehl-Neelsen technique. 
Each sample was decontaminated, ho-
mogenized, and concentrated by using 
the N-acetyl-L-cysteine-sodium hy-
droxide method. Samples were spread 
onto solid slants (Löwenstein-Jensen, 
Stonebrink; National Reference Center 
for Mycobacteria, Borstel, Germany) 
and inoculated into BACTEC Myco-
bacteria growth indicator tubes (MGIT 
960; Becton Dickinson and Company, 
Cockeysville, MD, USA). Solid slants 
were incubated at 31°C and 37°C for 8 
weeks and inspected for growth week-
ly. MGITs were incubated in and auto-
matically read with a BACTEC MGIT 
instrument. 
Results of nucleic acid ampliﬁ  ca-
tion for M. tuberculosis complex by 
using the BD ProbeTec system (Bec-
ton Dickinson and Company) as well 
as the ampliﬁ  cation of DNA coding 
for the mycobacterial 16S rRNA gene 
were negative. Growth of mycobac-
teria was detected after 12–17 days 
in liquid MGIT cultures. For species 
identiﬁ  cation of the cultures, part of 
the 16S rRNA gene was sequenced 
(7). The resulting sequences were 
compared with those in international 
databases (www.ridom.de; www.ncbi.
nlm.nih.gov/BLAST). The strains 
were identiﬁ  ed as M. bohemicum. 
To date, >125 nontuberculous my-
cobacteria species have been described 
(www.bacterio.cict.fr/m/mycobacte-
rium.html). Nontuberculous mycobac-
terial cervical lymphadenitis is most 
frequently caused by M. avium (80%), 
M. malmoense, M. kansasii, M. lentiﬂ  a-
vum, M. haemophilum, and M. scrofu-
laceum ( 8). Because the phenotypic 
characteristics of M. bohemicum close-
ly resemble those of M. scrofulaceum, 
these species can easily be misidentiﬁ  ed 
by analysis of biochemical and cultural 
features only. The technique by which 
M. bohemicum can clearly be identiﬁ  ed 
is sequence analysis (8,9).
Other than in the 4 patients re-
ported here, M. bohemicum infection 
has only been reported in 5 patients 
worldwide (3–6). Each was a child 
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Table. Characteristics of 4 children with cervical lymphadenitis caused by Mycobacterium bohemicum, Austria, 2002–2006* 
Patient
no. Sex; age Clinical findings Therapy Histologic findings
1 M; 2 y, 10 mo Right submandibular 
swelling
Incomplete surgical 
excision; clarithromycin and 
rifabutin for 3 mo
Granulomatous and partly necrotizing 
inflammation, multiple giant cells and perinodal 
fibrosis; no acid-fast bacilli
2† F; 2 y, 9 mo Right submandibular 
swelling
Total lymph node excision Granulomatous and partly necrotizing 
inflammation; acid-fast bacilli
3 F; 3 y Angular right-sided 
swelling
Total lymph node excision Granulomatous and partly necrotizing 
inflammation; sporadic findings of acid-fast bacilli
4 M; 3 y,  7 mo Swelling in right 
mandibular area
Total lymph node excision Granulomatous and partly necrotizing 
inflammation; no acid-fast bacilli
*All patients had negative PCR results for Mycobacterium tuberculosis complex; all patients recovered completely with no relapse. 
†Patient had history of psychomotor disorder after perinatal asphyxia. LETTERS
with laterocervical and submandibu-
lar lymphadenitis. Total lymph node 
excision was performed with a good 
outcome for all patients except 1, who 
required additional treatment with an-
timicrobial drugs because the infected 
lymph node was incompletely excised 
(4). Additionally, a systemic M. bohe-
micum infection associated with im-
munodeﬁ  ciency was reported recently 
(10). Treatment recommendations for 
nontuberculous mycobacterial lymph-
adenitis are outlined in discussions of 
individual nontuberculous mycobacte-
rium species. Guidelines for localized 
lymphadenitis caused by any non-
tuberculous mycobacterium species 
recommend complete surgical exci-
sion of the involved lymph nodes (8). 
Additional antimicrobial drug therapy 
is recommended only for patients for 
whom removal was incomplete (8). 
Our patient who received combina-
tion antimicrobial drug treatment im-
proved, with no relapse.
In summary we report 4 cases of 
M. bohemicum from Austria, a coun-
try with 8 million inhabitants. Because 
these cases were observed in a rela-
tively small country, infections with 
M. bohemicum may be more common 
than previously thought. More such 
cases may be discovered as a result 
of improved microbiologic diagnostic 
techniques. We believe that M. bohe-
micum should be listed among the spe-
cies that induce nontuberculous myco-
bacterial infections.
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Pertussis 
Surveillance in 
Private Pediatric 
Practices, France, 
2002–2006 
To the Editor: In France, pertus-
sis epidemiology has been extensively 
studied since 1993. Immunization 
of children with a highly efﬁ  cacious 
pertussis whole-cell (Pw) vaccine 
(Sanoﬁ   Pasteur MSD, Lyon, France) 
for 40 years (since 1966) has reduced 
the incidence of pertussis. It has been 
demonstrated that infectious or vacci-
nal immunity to pertussis wanes with 
time and that pertussis is no longer a 
pediatric disease (1–5). Transmission 
now occurs predominantly from ado-
lescents and adults to unvaccinated 
newborns.
From 1966 through 1995, pri-
mary vaccination against pertussis 
was administered to children at 3, 4, 
and 5 months of age, and a booster 
was given at ≈2 years of age. Since 
1995, primary vaccination has been 
administered at 2, 3, and 4 months of 
age, and a booster is given at 16–18 
months of age. Duration of protection 
of children immunized with Pw vac-
cine at these schedules is estimated to 
be ≈7–9 years (1,5). 
In response to the problem of 
waning immunity, a second pertussis 
booster immunization at 11–13 years 
of age was introduced in 1998 (6). De-
velopment of pertussis acellular (Pa) 
vaccines has enabled administration of 
this booster immunization. The French 
hospital network surveillance system 
(Renacoq) was established in 1996 
to monitor severe pertussis in infants 
and the effect of late booster immuni-
zations. A cyclic disease pattern was 
observed; peaks were noted for 1993, 
1997, 2000, and 2005. However, the 
last peak had a low amplitude; since 
then a diminution in the proportion of 
siblings who transmitted the infection 
to young infants was observed (2). 
These results could have been caused 
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